Form 4: Monopar Therapeutics Grants Options to Acting CMO

Monopar Therapeutics reported an equity grant of 2,000 stock options to Patrice Rioux, its Acting Chief Medical Officer, with an exercise price of $65.3.

Summary

• Patrice Rioux, Acting Chief Medical Officer of Monopar Therapeutics (MNPR), was granted 2,000 stock options.
• The options have an exercise price of $65.3 per share.
• The transaction date for the grant was January 1, 2026.
• The options will vest monthly, with 1/12th of the 2,000 options vesting on January 31, 2026, and each subsequent month-end thereafter.
• The options expire on January 1, 2036.
• Following this transaction, Patrice Rioux beneficially owns 2,000 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a positive for aligning management incentives with shareholder interests, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options aligns the interests of the Acting Chief Medical Officer, Patrice Rioux, with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date (January 1, 2036), providing a long window for potential value realization.

Negatives

• No specific negative points are identified in this Form 4 filing, which primarily reports an equity grant as part of compensation.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedule for the granted stock options extends through December 2026, indicating a long-term incentive structure for the Acting Chief Medical Officer.

Industry Context

Equity grants, such as stock options, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to attract and retain talent while aligning management incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: The grant aligns the Acting Chief Medical Officer's interests with shareholders, potentially leading to better long-term performance.
• Employees: Reflects standard executive compensation practices, which can be a positive for employee morale and retention if seen as fair and performance-based.

Next Steps

• Monthly vesting of the 2,000 stock options will continue, with 1/12th vesting at each month-end following January 31, 2026.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Patrice Rioux, stock options, equity grant, Chief Medical Officer, insider transaction, Form 4, compensation